Brainstorm cell therapeutics strengthens leadership team with appointment of kirk taylor, m.d., as executive vice president and chief medical officer

Dr. taylor has extensive biopharma industry expertise in neurodegenerative disease and experience leading drug launches and post-approval studies company begins a targeted capability build to prepare for anticipated growth new york , april 24, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of kirk taylor, m.d., as executive vice president and chief medical officer (evp, cmo), effective may 1, 2023.
BCLI Ratings Summary
BCLI Quant Ranking